Investigating the structure-activity relationships of N'-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against Trypanosoma cruzi to design novel active compounds.

[1]  B. Zingales Trypanosoma cruzi genetic diversity: Something new for something known about Chagas disease manifestations, serodiagnosis and drug sensitivity. , 2017, Acta tropica.

[2]  M. Lewis,et al.  Putting Infection Dynamics at the Heart of Chagas Disease. , 2016, Trends in parasitology.

[3]  Kerly F. M. Pasqualoto,et al.  Designing and exploring active N'-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against three Trypanosoma cruzi strains more prevalent in Chagas disease patients. , 2015, European journal of medicinal chemistry.

[4]  M. Miles,et al.  Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity , 2014, Memorias do Instituto Oswaldo Cruz.

[5]  E. Chatelain,et al.  Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development , 2014, Scientific Reports.

[6]  Kerly F. M. Pasqualoto,et al.  5-Nitro-2-furfuriliden derivatives as potential anti-Trypanosoma cruzi agents: design, synthesis, bioactivity evaluation, cytotoxicity and exploratory data analysis. , 2013, Bioorganic & medicinal chemistry.

[7]  D. Maria,et al.  Ligand-based design, synthesis, and experimental evaluation of novel benzofuroxan derivatives as anti-Trypanosoma cruzi agents. , 2013, European journal of medicinal chemistry.

[8]  A. Rassi,et al.  American trypanosomiasis (Chagas disease). , 2012, Infectious disease clinics of North America.

[9]  M. Lourenço,et al.  Synthesis and Antitubercular Activity of Novel Amino Acid Derivatives , 2012, Chemical biology & drug design.

[10]  Kerly F. M. Pasqualoto,et al.  Synthesis, molecular modeling and preliminary biological evaluation of a set of 3-acetyl-2,5-disubstituted-2,3-dihydro-1,3,4-oxadiazole as potential antibacterial, anti-Trypanosoma cruzi and antifungal agents. , 2011, Bioorganic & medicinal chemistry.

[11]  Kerly F. M. Pasqualoto,et al.  Novel benzofuroxan derivatives against multidrug-resistant Staphylococcus aureus strains: design using Topliss' decision tree, synthesis and biological assay. , 2011, Bioorganic & medicinal chemistry.

[12]  B. Hall,et al.  Nifurtimox Activation by Trypanosomal Type I Nitroreductases Generates Cytotoxic Nitrile Metabolites* , 2011, The Journal of Biological Chemistry.

[13]  B. Zingales,et al.  Trypanosoma cruzi benznidazole susceptibility in vitro does not predict the therapeutic outcome of human Chagas disease. , 2010, Memorias do Instituto Oswaldo Cruz.

[14]  J. Urbina Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. , 2010, Acta tropica.

[15]  J. Coura,et al.  Chagas disease: a new worldwide challenge , 2010, Nature.

[16]  J. Zock,et al.  Applications of High Content Screening in Life Science Research , 2009, Combinatorial chemistry & high throughput screening.

[17]  A. Romanha,et al.  A new consensus for Trypanosoma cruzi intraspecific nomenclature: second revision meeting recommends TcI to TcVI. , 2009, Memorias do Instituto Oswaldo Cruz.

[18]  Christine Humblet,et al.  GARD: A Generally Applicable Replacement for RMSD , 2009, J. Chem. Inf. Model..

[19]  Cun‐Kui Li,et al.  Synthesis of Novel 3‐Acetyl‐2‐Aryl‐5‐(3‐Aryl‐1‐Phenyl‐Pyrazol‐4‐yl)‐2,3‐Dihydro‐1,3,4‐Oxadiazoles , 2009 .

[20]  D. Horn,et al.  A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes , 2008, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Márcia M. C. Ferreira,et al.  Quimiometria I: calibração multivariada, um tutorial , 1999 .

[22]  G. Peluffo,et al.  1,2,5-Oxadiazole N-oxide derivatives and related compounds as potential antitrypanosomal drugs: structure-activity relationships. , 1999, Journal of medicinal chemistry.

[23]  Randall D. Tobias,et al.  Chemometrics: A Practical Guide , 1998, Technometrics.

[24]  A. T. Amaral,et al.  Synthesis and biological activity of nifuroxazide and analogs. , 1997, Bollettino chimico farmaceutico.

[25]  Shaomeng Wang,et al.  Computer Automated log P Calculations Based on an Extended Group Contribution Approach , 1994, J. Chem. Inf. Comput. Sci..

[26]  S. G. Andrade,et al.  Specific chemotherapy of Chagas disease: a comparison between the response in patients and experimental animals inoculated with the same strains. , 1992, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[27]  G. A. Petersson,et al.  A complete basis set model chemistry. II. Open‐shell systems and the total energies of the first‐row atoms , 1991 .

[28]  C. Breneman,et al.  Determining atom‐centered monopoles from molecular electrostatic potentials. The need for high sampling density in formamide conformational analysis , 1990 .

[29]  Arup K. Ghose,et al.  Atomic physicochemical parameters for three dimensional structure directed quantitative structure-activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics , 1989, J. Chem. Inf. Comput. Sci..

[30]  A. Becke,et al.  Density-functional exchange-energy approximation with correct asymptotic behavior. , 1988, Physical review. A, General physics.

[31]  Parr,et al.  Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density. , 1988, Physical review. B, Condensed matter.

[32]  L. Filardi,et al.  Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. , 1987, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[33]  S. Croft In vitro screens in the experimental chemotherapy of leishmaniasis and trypanosomiasis. , 1986, Parasitology today.

[34]  Eamonn F. Healy,et al.  Development and use of quantum mechanical molecular models. 76. AM1: a new general purpose quantum mechanical molecular model , 1985 .

[35]  Norman L. Allinger,et al.  Conformational analysis. 130. MM2. A hydrocarbon force field utilizing V1 and V2 torsional terms , 1977 .

[36]  A. J. Hopfinger,et al.  The Influence of Solvent on the Secondary Structures of Poly(L-alanine) and Poly(L-proline) , 1973 .

[37]  J. Pontén,et al.  Two established in vitro cell lines from human mesenchymal tumours , 1967, International journal of cancer.

[38]  Didier Rognan,et al.  The practice of medicinal chemistry , 2015 .

[39]  L. M. Lima,et al.  Hybrid furoxanyl N-acylhydrazone derivatives as hits for the development of neglected diseases drug candidates. , 2013, European journal of medicinal chemistry.

[40]  B. Pniewska,et al.  Structural Investigations of Nifuroxazide, p-Hydroxy-N'-(5-nitrofurfurylidene)benzhydrazide , 1998 .

[41]  P. Mahalanobis On the generalized distance in statistics , 1936 .